Table 3. Analysis of prognostic factors... | American Society of Hematology

Table 3.

Analysis of prognostic factors (univariate analysis)

		Overall survival at 1 year			Relapse-free survival at 1 year
	No. of patients	% survival	P	% survival	P	% TRM	P
Patient sex			.86		.99		.68
Male	18	44.4		38.9		48.4
Female	11	43.6		45.4		45.5
Patient age^*			.85		.94		.61
Younger than 60 y	17	47.1		41.2		48.2
60 y or older	12	38.9		40.0		48.1
Donor sex			.64		.61		.21
Male	23	43.5		39.1		52.9
Female	6	50.0		50.0		25.0
Patient CMV status			.65		.62		.47
Reactive	10	50.0		50.0		33.3
Nonreactive	19	42.1		36.8		53.7
Donor CMV status			.84		.75		.71
Reactive	17	46.3		46.3		45.2
Nonreactive	12	41.7		33.3		51.4
HLA matching			.09		.07		.01
Matched	23	51.2		46.8		38.3
Mismatched	6	16.7		16.7		83.3
Time to transplantation^*			.83		.76		.52
18 mo or longer	15	45.7		38.1		54.3
Less than 18 mo	14	42.9		42.9		38.8
Disease status at transplantation for AML/MDS
Sensitive	4	75.0		75.0		25.0
Refractory	11	12.1	.03	13.6	.03	79.5	.07
Untreated	5	60.0	.54	60.0	.30	20.0	.98
Use of ATG in conditioning
Yes	17	51.3	.28	45.3	.25	38.8	.24
No	12	33.0		25.0		51.9
CD34⁺ cell dose^*			.35		.66		.53
4.46 × 10⁶/kg or more	15	53.3		46.6		41.8
Less than 4.46 × 10⁶/kg	14	32.6		33.3		57.1

		Overall survival at 1 year			Relapse-free survival at 1 year
	No. of patients	% survival	P	% survival	P	% TRM	P
Patient sex			.86		.99		.68
Male	18	44.4		38.9		48.4
Female	11	43.6		45.4		45.5
Patient age^*			.85		.94		.61
Younger than 60 y	17	47.1		41.2		48.2
60 y or older	12	38.9		40.0		48.1
Donor sex			.64		.61		.21
Male	23	43.5		39.1		52.9
Female	6	50.0		50.0		25.0
Patient CMV status			.65		.62		.47
Reactive	10	50.0		50.0		33.3
Nonreactive	19	42.1		36.8		53.7
Donor CMV status			.84		.75		.71
Reactive	17	46.3		46.3		45.2
Nonreactive	12	41.7		33.3		51.4
HLA matching			.09		.07		.01
Matched	23	51.2		46.8		38.3
Mismatched	6	16.7		16.7		83.3
Time to transplantation^*			.83		.76		.52
18 mo or longer	15	45.7		38.1		54.3
Less than 18 mo	14	42.9		42.9		38.8
Disease status at transplantation for AML/MDS
Sensitive	4	75.0		75.0		25.0
Refractory	11	12.1	.03	13.6	.03	79.5	.07
Untreated	5	60.0	.54	60.0	.30	20.0	.98
Use of ATG in conditioning
Yes	17	51.3	.28	45.3	.25	38.8	.24
No	12	33.0		25.0		51.9
CD34⁺ cell dose^*			.35		.66		.53
4.46 × 10⁶/kg or more	15	53.3		46.6		41.8
Less than 4.46 × 10⁶/kg	14	32.6		33.3		57.1

TRM indicates transplant-related mortality

Above and below the median.